Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Misselwitz · SciRah

Researcher profile · Semantic Scholar

F. Misselwitz

Share profile

F. Misselwitz — researcher profile on SciRah

h-index: 46
Works: 169
Citations: 20K

Most-cited papers

Oral rivaroxaban for symptomatic venous thromboembolism.
R. Bauersachs, S. Berkowitz, B. Brenner, H. Buller +15 more
2010New England Journal of Medicine2,232 citations Open access
Semantic Scholar
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. Eikelboom, S. Connolly, J. Bosch, G. Dagenais +45 more
2017New England Journal of Medicine2,050 citations Open access
Semantic Scholar
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
H. Büller, M. Prins, A. Lensin, H. Décousus +15 more
2012New England Journal of Medicine1,731 citations Open access
Semantic Scholar
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
B. Eriksson, L. Borris, R. Friedman, S. Haas +7 more
2008New England Journal of Medicine1,478 citations Open access
Semantic Scholar
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
M. Lassen, W. Ageno, L. Borris, J. Lieberman +4 more
2008New England Journal of Medicine1,351 citations Open access
Semantic Scholar
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
A. Kakkar, B. Brenner, O. Dahl, B. Eriksson +6 more
2008The Lancet1,138 citations Open access
Semantic Scholar
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
A. Turpie, M. Lassen, B. Davidson, K. Bauer +9 more
2009The Lancet998 citations
Semantic Scholar
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Sonia S Anand, J. Bosch, J. Eikelboom, S. Connolly +28 more
2018The Lancet708 citations Open access
Semantic Scholar
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
J. Mega, E. Braunwald, Satishkumar Mohanavelu, Paul R. Burton +9 more
2009The Lancet668 citations
Semantic Scholar
Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
A. Kakkar, I. Mueller, J. Bassand, D. Fitzmaurice +13 more
2013PLoS ONE474 citations Open access
Semantic Scholar
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
H. Buller, A. Lensing, M. Prins, G. Agnelli +6 more
2008Blood337 citations
Semantic Scholar
Developing Therapies for Heart Failure with Preserved Ejection Fraction: Current State and Future Directions
J. Butler, G. Fonarow, M. Zile, C. Lam +28 more
2014JACC. Heart failure333 citations Open access
Semantic Scholar
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
W. Mueck, A. Lensing, G. Agnelli, H. Décousus +2 more
2011Clinical Pharmacokinetics313 citations
Semantic Scholar
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
E. Perzborn, S. Roehrig, A. Straub, D. Kubitza +1 more
2011Nature reviews. Drug discovery300 citations
Semantic Scholar
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
W. Mueck, L. Borris, O. Dahl, S. Haas +6 more
2008Thrombosis and Haemostasis287 citations
Semantic Scholar
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
J. Bassand, G. Accetta, A. Camm, F. Cools +13 more
2016European Heart Journal278 citations Open access
Semantic Scholar
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery
W. Mueck, B. Eriksson, K. Bauer, L. Borris +10 more
2008Clinical Pharmacokinetics251 citations
Semantic Scholar
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty
A. Turpie, M. Lassen, B. Eriksson, M. Gent +6 more
2010Thrombosis and Haemostasis243 citations
Semantic Scholar
Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
A. Camm, G. Accetta, G. Ambrosio, D. Atar +15 more
2016Heart240 citations Open access
Semantic Scholar
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD).
A. Kakkar, I. Mueller, J. Bassand, D. Fitzmaurice +11 more
2012American Heart Journal240 citations
Semantic Scholar
Erratum to: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention
W. Mueck, A. Lensing, G. Agnelli, H. Décousus +2 more
2011Clinical Pharmacokinetics198 citations
Semantic Scholar
Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
S. Haas, H. ten Cate, G. Accetta, P. Angchaisuksiri +17 more
2016PLoS ONE157 citations Open access
Semantic Scholar
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.
J. Bosch, J. Eikelboom, S. Connolly, N. C. Bruns +54 more
2017Canadian Journal of Cardiology154 citations Open access
Semantic Scholar
Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
K. A. Fox, J. Lucas, K. Pieper, J. Bassand +14 more
2017BMJ Open141 citations Open access
Semantic Scholar
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
B. Eriksson, A. Kakkar, A. Turpie, M. Gent +4 more
2009Journal of Bone and Joint Surgery-british Volume107 citations Open access
Semantic Scholar
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry
J. Bassand, S. Virdone, S. Goldhaber, A. Camm +13 more
2019Circulation79 citations Open access
Semantic Scholar
Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry.
Seil Oh, S. Goto, G. Accetta, P. Angchaisuksiri +9 more
2016International Journal of Cardiology74 citations
Semantic Scholar
Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
V. Laux, E. Perzborn, S. Heitmeier, G. von Degenfeld +4 more
2009Thrombosis and Haemostasis73 citations
Semantic Scholar
Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions
M. Gheorghiade, M. Vaduganathan, S. Greene, R. Mentz +23 more
2014Heart Failure Reviews63 citations Open access
Semantic Scholar
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.
J. Bassand, S. Virdone, M. Badoz, F. Verheugt +13 more
2021Blood Advances59 citations Open access
Semantic Scholar
A call to action for new global approaches to cardiovascular disease drug solutions.
G. Figtree, Keith Broadfoot, B. Casadei, R. Califf +18 more
2021European Heart Journal54 citations Open access
Semantic Scholar
Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives.
M. Gheorghiade, A. Shah, M. Vaduganathan, J. Butler +7 more
2013Heart Failure Clinics54 citations
Semantic Scholar
Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry
F. Cools, Dana Johnson, A. Camm, J. Bassand +13 more
2021Journal of Thrombosis and Haemostasis51 citations Open access
Semantic Scholar
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
S. Haas, A. Camm, J. Bassand, P. Angchaisuksiri +18 more
2019American Heart Journal51 citations Open access
Semantic Scholar
GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
K. Fox, S. Virdone, K. Pieper, J. Bassand +13 more
2021European Heart Journal - Quality of Care and Clinical Outcomes46 citations Open access
Semantic Scholar
New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF
Shinichi Goto, S. Goto, K. Pieper, J. Bassand +12 more
2019European Heart Journal - Cardiovascular Pharmacotherapy42 citations Open access
Semantic Scholar
Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.
R. Corbalán, J. Bassand, L. Illingworth, G. Ambrosio +13 more
2019JAMA cardiology42 citations Open access
Semantic Scholar
Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease
P. Vranckx, F. Leebeek, J. Tijssen, J. Koolen +11 more
2015Thrombosis and Haemostasis42 citations Open access
Semantic Scholar
The discovery and development of rivaroxaban
F. Misselwitz, S. Berkowitz, E. Perzborn
2011Annals of the New York Academy of Sciences40 citations
Semantic Scholar
A Pooled Analysis of Four Pivotal Studies of Rivaroxaban for the Prevention of Venous Thromboembolism after Orthopaedic Surgery: Effect on Symptomatic Venous Thromboembolism, Death, and Bleeding
A. Turpie, M. Lassen, A. Kakkar, B. Eriksson +5 more
200839 citations
Semantic Scholar
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
D. Kubitza, S. Berkowitz, F. Misselwitz
2016Clinical and applied thrombosis/hemostasis38 citations Open access
Semantic Scholar
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation
Keith A. A. Fox, P. Velentgas, A. Camm, J. Bassand +13 more
2020JAMA Network Open37 citations Open access
Semantic Scholar
Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry
F. Verheugt, Hai-Yan Gao, W. Al Mahmeed, G. Ambrosio +12 more
2018European Heart Journal37 citations
Semantic Scholar
Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry
A. Camm, G. Accetta, W. Al Mahmeed, G. Ambrosio +11 more
2017BMJ Open36 citations Open access
Semantic Scholar
The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events
D. Atar, E. Berge, J. le Heuzey, S. Virdone +11 more
2019Europace34 citations Open access
Semantic Scholar
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators.
J. Butler, G. Fonarow, C. O'Connor, K. Adams +21 more
2015American Heart Journal25 citations
Semantic Scholar
A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions.
G. Figtree, Keith Broadfoot, B. Casadei, R. Califf +18 more
2021Circulation22 citations Open access
Semantic Scholar
Comparative effectiveness of oral anticoagulants in everyday practice
A. Camm, K. Fox, S. Virdone, J. Bassand +12 more
2021Heart20 citations Open access
Semantic Scholar
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis‐mediated conditions
Troy C. Sarich, G. Peters, S. Berkowitz, F. Misselwitz +16 more
2013Annals of the New York Academy of Sciences20 citations
Semantic Scholar
Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4
A. Turpie, K. Bauer, B. Davidson, M. Gent +8 more
200819 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Turpie×23
Invite
A. Turpie — researcher profile on SciRah
A. Kakkar×21
Invite
A. Kakkar — researcher profile on SciRah
S. Haas×20
Invite
S. Haas — researcher profile on SciRah
A. Camm×17
Invite
A. Camm — researcher profile on SciRah

×14

Invite

J. Bassand — researcher profile on SciRah

Invite

S. Goto — researcher profile on SciRah

Invite

G. Kayani — researcher profile on SciRah

F. Verheugt×11

Invite

F. Verheugt — researcher profile on SciRah

S. Goldhaber×10

Invite

S. Goldhaber — researcher profile on SciRah

S. Berkowitz×8

Invite

S. Berkowitz — researcher profile on SciRah

Invite

K. Fox — researcher profile on SciRah

Invite

K. Pieper — researcher profile on SciRah